NF2 and neoplasm: Interestingly, FAK inhibitor monotherapy has already shown significant clinical activity in other solid cancers, with pronounced efficacy in cancers that harbour loss of specific tumour suppressive signals, such as merlin (encoded by NF2 gene), both in preclinical models [122] and clinical studies [123].